Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Acta Biol Hung ; 52(1): 179-85, 2001.
Artigo em Inglês | MEDLINE | ID: mdl-11396838

RESUMO

Lemna minor is a species easy to collect and culture in laboratory, and can give rapid test results. However, in order to standardise toxicity tests using Lemna minor as test organism, it is important to find out what natural variability different populations might have. Five Lemna populations were used for comparison. It contained two standard cultures and three populations collected in natural habitats. Potassium dichromate was applied as test material. Lemna populations cultured under the same conditions showed different T(D) and LC50 values. There is an inverse relation between the sensitivity and T(D) of the strains. It is supposed that growth rate and sensitivity of Lemna populations depend on environmental factors characterising the habitat in which the given popluation originally lives.


Assuntos
Magnoliopsida/efeitos dos fármacos , Testes de Toxicidade/normas , Reprodutibilidade dos Testes
2.
Arterioscler Thromb Vasc Biol ; 17(11): 2861-7, 1997 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-9409267

RESUMO

On the basis of an array of preclinical experimental results, it has been widely assumed that endothelin-1 (ET-1) may affect blood coagulation, fibrinolysis, and endothelial cell function, thereby playing a pathophysiological role in various cardiovascular diseases in humans. However, confirmation of this assumption is still lacking. ET-1 or placebo was administered intravenously to 12 healthy volunteers in a prospective, randomized, double-blind, crossover trial. Pathophysiologically relevant concentrations of ET-1 (an approximate threefold increase of normal blood levels) causing hemodynamic effects were reached by continuous intravenous infusion for 6 hours. Components of the coagulation (thrombin-antithrombin complexes, prothrombin fragment F1 + 2, activated factor VII, and factor VII antigen) and fibrinolytic (fibrin split product D-dimer, plasmin-plasmin inhibitor complex, tissue-type plasminogen activator, urokinase-type plasminogen activator, and plasminogen activator inhibitor-1) systems and markers of endothelial cell perturbation/dysfunction (von Willebrand factor and thrombomodulin) were measured before the start of infusion and after 2, 6, 12, and 24 hours. Comparing changes in the plasma concentrations of these parameters during and after infusion of ET-1 and placebo, we found no specific effects of ET-1. In contrast to previous reports from preclinical experiments, ET-1 does not appear to affect coagulation or fibrinolysis, nor does this peptide induce relevant endothelial cell perturbations in humans.


Assuntos
Coagulação Sanguínea/efeitos dos fármacos , Endotelina-1/farmacologia , Endotélio Vascular/efeitos dos fármacos , Fibrinólise/efeitos dos fármacos , Hemodinâmica/efeitos dos fármacos , Adulto , Estudos Cross-Over , Método Duplo-Cego , Hemoglobinas/análise , Humanos , Insulina/sangue , Masculino , Projetos Piloto , Inibidor 1 de Ativador de Plasminogênio/sangue , Estudos Prospectivos , Circulação Renal/efeitos dos fármacos , Ativador de Plasminogênio Tecidual/sangue , Ativador de Plasminogênio Tipo Uroquinase/sangue , Ácido p-Aminoipúrico/sangue , Fator de von Willebrand/análise
3.
Eur J Clin Invest ; 27(10): 850-6, 1997 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-9373765

RESUMO

Several studies point to a role for endothelin-1 (ET-1) in enhancing adhesion molecule expression and leucocyte adhesion. We thus hypothesized that ET-1 would induce expression of adhesion molecules by endothelial cells and by leucocytes in humans, and hence compared with placebo the effect of a continuous 6-h ET-1 infusion on plasma levels of circulating (c)E-selectin, cP-selectin, intercellular and vascular cell adhesion molecule 1. In addition, we investigated the effects of ET-1 on expression of the leucocyte adhesion molecules CD11b/CD18 and L-selectin on monocytes and neutrophils. After an open pilot study to evaluate the safety of a 6-h ET-1 infusion of 0.4 pmol kg-1 min-1 (n = 4), the main study was conducted as a randomized, double-blind, two-way, cross-over trial in 12 additional young healthy male volunteers, who received the same treatment and were observed over a period of 24 h. ET-1 infusion decreased renal plasma flow by 43% (CI 35-51%; P < 0.001) and increased the filtration fraction by 80% (CI 20-110%; P < 0.001). Heart rate decreased by -10% (CI -4% to -15%) at 6 h under ET-1 infusion in the cross-over trial (P = 0.012 between periods). Although ET-1 infusions increased plasma levels of ET-1 by about 300%, ET-1 elicited no relevant changes in any circulating adhesion molecules or leucocyte adhesion molecules measured. In the placebo period small diurnal changes were observed for cP-selectin (-8%, CI -14 to -3%, P = 0.008) and cE-selectin (-6%, CI -10 to -3%, P = 0.003) at 12 h (20.45 h). In sum, ET-1 does not regulate circulating adhesion molecules in healthy men. Circadian variations may exist for plasma levels of cP-selectin and cE-selectin.


Assuntos
Moléculas de Adesão Celular/sangue , Endotelina-1/farmacologia , Adulto , Antígenos CD11/análise , Antígenos CD18/análise , Estudos Cross-Over , Método Duplo-Cego , Endotelina-1/sangue , Hemodinâmica/efeitos dos fármacos , Humanos , Molécula 1 de Adesão Intercelular/sangue , Masculino , Projetos Piloto , Molécula 1 de Adesão de Célula Vascular/sangue
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...